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Introduction
In the phase 3 TENDER trial of TCZ in patients with sJIA,
decreases in neutrophil count were commonly observed.
Objectives
To determine if neutropenia was associated with increased
risk of infection and to investigate variables associated
with development of neutropenia in patients treated with
TCZ for up to 2 years in TENDER.
Methods
112 children with active, persistent sJIA were randomised
2:1 to receive TCZ by body weight (12 mg/kg <30kg or
8 mg/kg ≥30kg) or placebo IV every 2 weeks for 12 weeks
and continued in an ongoing, TCZ open-label extension.
[1]. Worst common toxicity criteria (CTC) neutropenia
grade (grade 1, ≥1.5 and <2.0 × 109/L; grade 2, ≥1.0 and
<1.5 × 109/L; grade 3, ≥0.5 and <1.0 × 109/L; grade 4, <0.5
× 109/L) and lowest observed neutrophil count (109/L)
were identified for each patient. Univariate linear regres-
sion analysis was performed to investigate association of
patient characteristics with lowest observed neutrophil
count. Rates of infections and serious infections (per 100
patient years [PY]) in periods ± 15 days around grade1-2
neutropenia (22.9 PY) and around grade 3-4 neutropenia
(5.5 PY) were compared to corresponding rates in periods
with normal neutrophil count (173.6 PY).
Results
Up to week 104, 64/112 patients (57.1%) had at least 1 epi-
sode of grade 1-4 neutropenia; worst grade: 1 (n = 2),
2 (n = 34), 3 (n = 26) and 4 (n = 2). Rates of infections
and serious infections during period of normal neutrophil
counts (276.5/100PY [95% CI 252.3, 302.3] and 11.5/
100PY [95% CI 7.0, 17.8], respectively) were comparable
to those observed ±15 days around grade 1-2 neutropenia
(226.7/100PY [95% CI 169.3, 297.3]; 8.7/100PY [95% CI
1.1, 31.5]) and grade 3-4 neutropenia (292.5/100PY [95%
CI 167.2, 475.0]; 0/100PY), with no trend towards
increased risk with higher grade neutropenia. Methotrex-
ate (MTX) use (Yes/No) was significantly associated with
lowest observed neutrophil count (difference: -0.575 [95%
CI: -1.02, -0.13], p = 0.012), with 62% of 77 patients receiv-
ing MTX vs 46% of 35 patients not receiving MTX having
grade 1-4 neutropenia. Younger age was borderline asso-
ciated with lowest observed neutrophil count (b = 0.04661,
p = 0.047). Concurrent use of glucocorticoids (GC) and
TCZ exposure were not associated with lowest observed
neutrophil count (p>0.3).
Conclusion
No trend for association between neutropenia and
increased risk of infections was observed in the TENDER
trial. Background MTX, and somewhat younger age, was
associated with increased risk for neutropenia, while
TCZ exposure and concurrent GC use were not.
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